WHO gives prequalification to GSK's four-dose pneumococcal vaccine

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said the World Health Organization (WHO) gave prequalification to a 4-dose vial of pneumococcal vaccine Synflorix, which is intended to reduce the physical space required for storage. The new vial is intended mainly for countries supported by the Global Alliance for Vaccines and Immunization (GAVI), an international organization to improve access to new and underused vaccines for children in the world's poorest countries.

Local registration for the 4-dose vial in GAVI-supported countries is ongoing. Synflorix received Kenyan approval in September, with GSK expecting to start supplying the vaccine in 2018...